# Wu Yifang

> Wu Yifang is a corporate round investor at Fosun Pharma backing Artificial Intelligence. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Fosun Pharma](https://shizune.co/investors/profile/fosun-pharmaceutical)
- Location: Shanghai, China
- Total investments: 2
- Last investment: Aug 2022
- Lead investor: 100%
- Last updated: Aug 2026

Wu Yifang is a corporate round investor at Fosun Pharma in Shanghai focused on Artificial Intelligence and Health Care. Wu Yifang is based out of Shanghai, Shanghai and is the senior vice president and chief operating officer of Fosun Pharma. Wu previously worked at Wanbang Pharma as a director. Wu Yifang attended Saint Joseph’s University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 2 | 100% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |
| Pharmaceutical | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Corporate Round | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 50% |
| Hong Kong | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xingmai Technology | Xingmai Technology is a scientific and technological innovation-oriented enterprise. | $14.8M | Venture - Series Unknown | Aug 02, 2022 |  |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. |  | Corporate Round | Jan 11, 2022 |  |

2 of 2 investments shown.

## Co-investors
- [Shanghai Anting Industrial Development Co., Ltd.](https://shizune.co/investors/profile/shanghai-anting-industrial-development-co-ltd) — VC Fund, 1 deal together
- [Sinopharm-CICC](https://shizune.co/investors/profile/sinopharm-cicc) — VC Fund, 1 deal together

## About Fosun Pharma

VC Fund · Shanghai, China

Fosun Pharma is a biopharmaceutical and healthcare industry. Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industryvalue-chain, including: pharmaceutical manufacturing, distribution and retail.

5 contacts available at Fosun Pharma.

| Name | Title | Profile |
| --- | --- | --- |
| Cui Zhiping | Vice President and General Manager of VC Investment Department | https://shizune.co/investors/profile/cui-zhiping |
| Hongfei Jia | SVP, Joint Chief Investment Officer and General Manager of International Operations Department | https://shizune.co/investors/profile/hongfei-jia |
| Wai Danny | Independent Non-Executive Director | https://shizune.co/investors/profile/wai-danny |
| Wu Yifang | Senior vice president and Chief operating officer | https://shizune.co/investors/profile/wu-yifang |
| Zhou Biao | SVP, General Manager of Legal Department and General Manager of Independent Inspectors Department | https://shizune.co/investors/profile/zhou-biao |

## Similar investors

### Similar stage
- [Info Edge](https://shizune.co/investors/profile/info-edge) — VC Fund
- [Vector](https://shizune.co/investors/profile/vector-inc-) — VC Fund
- [Akatsuki Games Inc.](https://shizune.co/investors/profile/akatsuki-3) — VC Fund

## FAQ

### What does Wu Yifang invest in?

Wu Yifang invests primarily in Artificial Intelligence, Health Care and Biotechnology startups, most often at Corporate Round and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wu Yifang last invest?

The most recent investment recorded for Wu Yifang closed in Aug 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co